The Outcome of Tisagenlecleucel (Tisa-Cel) Vs Axicabtagene Ciloleucel (Axi-Cel) CD-19 CAR-T Cell Therapy in Relapsed/Refractory NHL, Real World Data, Single Institution Experience

被引：0

作者：

Alasbali, Reem ^{[1
]}

Nasiri, Abdulrahman ^{[1
]}

Adam, Alfadil ^{[1
]}

Alhayli, Saud ^{[1
]}

Chaudhri, Naeem A. ^{[1
]}

Alshaibani, Alfadel ^{[1
]}

Albabtain, Abdulwahab ^{[1
]}

Samarkandi, Hadeel ^{[2
]}

Saad, Ayman ^{[1
]}

Alamer, Abdullah ^{[1
]}

Elhassan, Tusneem Ahmed M. ^{[2
]}

Alzahrani, Hazza A. ^{[1
]}

Ahmed, Syed Osman ^{[1
]}

Rasheed, Walid ^{[1
]}

Elfakih, Riad ^{[1
]}

Aljurf, Mahmoud ^{[1
]}

Ali, D. Alahmari ^{[1
]}

机构：

[1] KFSHRC, Dept Hematol, Stem Cell Transplantat & Cellular Therapy, Riyadh, Saudi Arabia

[2] King Faisal Specialist Hosp & Res Ctr, Riyadh, Saudi Arabia

来源：

BLOOD | 2023年 / 142卷

关键词：

NHL; FL; CAR-T; CRS; ICANS;

D O I：

10.1182/blood-2023-182580

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 47 条

[21] Real World Outcomes with Idecabtagene Vicleucel ( Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Sidana, Surbhi
Ahmed, Nausheen
Akhtar, Othman S.
Heim, Michael
Brazauskas, Ruta
Hansen, Doris K.
Ferreri, Christopher
Freeman, Ciara Louise L.
Afrough, Aimaz
Anderson, Larry D., Jr.
Dhakal, Binod
Dhanda, Devender
Gowda, Lohith
Hashmi, Hamza
Harrison, Melanie
Kitali, Amani
Mirza, Sayeef
Patel, Jinalben
Patwardhan, Pallavi
Usmani, Saad Z.
Patel, Krina K.
Ganguly, Siddhartha
Pasquini, Marcelo
BLOOD, 2023, 142
[22] ZUMA-1 Pivotal Phase 2 Trial of Axicabtagene Ciloleucel (axi-cel, KTE-C19; Anti-CD19 CAR T Cells) in Patients (pts) with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
Neelapu, Sattva S.
Locke, Frederick L.
Ghobadi, Armin
Lekakis, Lazaros J.
Miklos, David
Jacobson, Caron A.
Braunschweig, Ira
Oluwole, Olalekan
Siddiqi, Tanya
Lin, Yi
Timmerman, John
Stiff, Patrick J.
Flinn, Iann
Goy, Andre
Smith, Mitchell
Deol, Abhinav
Farooq, Umar
McSweeeny, Peter
Munoz, Javier
Avivi, Irit
Reagan, Patrick
Bot, Adrian
Rossi, John
Navale, Lynn
Jiang, Yizhou
Aycock, Jeff
Elias, Meg
Wiezorek, Jeff
Go, William Y.
MOLECULAR THERAPY, 2017, 25 (05) : 333 - 333
[23] Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 13 - 15
[24] Axicabtagene Ciloleucel CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real-World Experience
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 9 - 10
[25] Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)
Pasquini, Marcelo C.
Locke, Frederick L.
Herrera, Alex F.
Siddiqi, Tanya
Ghobadi, Armin
Komanduri, Krishna V.
Hu, Zhen-Huan
Dong, Hua
Hematti, Peiman
Nikiforow, Sarah
Steinert, Patricia
Purdum, Anna
Horowitz, Mary M.
Hooper, Michelle
Kawashima, Jun
Jacobson, Caron A.
BLOOD, 2019, 134
[26] Clinical Outcomes of CD19 CAR-T-Cell Therapy with Axi-Cel in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) with and without Prior Autologous Stem Cell Transplant
Chen, David Tong
Goloubeva, Olga
Alkhaldi, Hanan
Rapoport, Aaron P.
Dahiya, Saurabh
Hardy, Nancy M.
Atanackovic, Djordje
Kocoglu, Mehmet Hakan
Lutfi, Forat
Yared, Jean A.
BLOOD, 2022, 140 : 9526 - 9527
[27] Tumor microenvironment immune gene signature asscoiated with axicabtagene ciloleucel (axi-cel, KTE-C19), an anti-CD19 chimeric antigen receptor (CAR) T cell, in a multicenter trial (ZUMA-1)
Rossi, John
Galon, Jerome
Turcan, Sarah
Danan, Corinne
Locke, Frederick
Neelapu, Sattva
Miklos, David
Bartlett, Nancy
Jacobson, Caron
Braunschweig, Ira
Oluwole, Olalekan
Siddiqi, Tanya
Lin, Yi
Timmerman, John
Reagan, Patrick
Lekakis, Lazaros
Unabia, Sherryonne
Go, William
Wiezorek, Jeff
Bot, Adrian
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
[28] Efficacy and Safety of CD19-Targeted CAR-T Cell Therapy for Refractory/Relapsed B-Cell Lymphoma: A Single Center of Real World Data
Huang, Jing
Fei, Jia
Ou, Ruiming
Liu, Zhi
Zheng, Liling
Zhu, Yangmin
Shen, Huijuan
Du, Yuanyuan
Zhou, Qinjun
Chen, Jiali
Zhou, Changhua
Yan, Rongrong
Wang, Jiale
Liu, Shuang
Zhang, Qing
BLOOD, 2021, 138
[29] Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).
Galon, Jerome
Rossi, John
Turcan, Sarah
Danan, Corinne
Locke, Frederick Lundry
Neelapu, Sattva Swarup
Miklos, David Bernard
Bartlett, Nancy L.
Jacobson, Caron Alyce
Braunschweig, Ira
Oluwole, Olalekan O.
Siddiqi, Tanya
Lin, Yi
Timmerman, John
Reagan, Patrick Michael
Lekakis, Lazaros J.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[30] Real-world experience of axicabtagene ciloleucel, a CD19-directed CAR T-cell therapy, in the second-line treatment of early relapsed or primary refractory large B-cell lymphoma
Othman, Tamer
Baird, John H.
Pak, Stacy
Mei, Matthew
Herrera, Alex F.
Mansour, Joshua
Shouse, Geoffrey
Sahebi, Firoozeh
Spielberger, Ricardo
Cai, Ji-Lian
Farol, Leonardo
Godfrey, James
Kallam, Avyakta
Phillips, Tycel
Popplewell, Leslie
Siddiqi, Tanya
Forman, Stephen
Budde, Lihua E.
BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (01) : 368 - 372

← 1 2 3 4 5 →